secwatch.observer — SEC 8-K summary
======================================

Issuer:     VACCINEX, INC. (VCNX)
CIK:        0001205922
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001193125-24-200272
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaccinex reports pepinemab slows cognitive decline in MCI due to AD; plans partnership
--------------------------------------------------------------------------------

- Pepinemab showed significant reduction in brain metabolic decline (FDG-PET) in medial temporal cortex (p=0.0297) vs placebo.
- In MCI patients, reduced astrocyte reactivity (GFAP) and neuronal damage marker p-tau217; no effect in early dementia.
- Cognitive decline slowed in MCI per iADRS and ADAS-Cog13; no benefit in early dementia group.
- Company plans to pursue a development partnership to reduce operating expenses going forward.
- Pepinemab was well-tolerated, consistent with prior Huntington's disease studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1205922/000119312524200272/0001193125-24-200272-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1205922/000119312524200272/d838109d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-200272

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer